ClinicalTrials.gg
CompletedNCT05536752AMENDUpdated Oct 1, 2026Results posted

QA102 Phase II Study in Subjects With Dry AMD

A Phase 2 interventional study of QA102/Placebo and QA102 in Dry Age-related Macular Degeneration, sponsored by Smilebiotek Zhuhai Limited. Completed at 29 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Smilebiotek Zhuhai Limited · Phase 2, Interventional, and Treatment

How we know

Updated Oct 1, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Enrollment
139th of 491
150 · median 55
Started
2022
with 35 others
Phase 2
138 of 645
14 open now
Registered
523rd of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 139th largest by enrollment of the 491 interventional ones that give a count, is one of 36 that started in 2022, is one of 138 in phase 2, and was the 523rd registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA), and geographic atrophy (GA) or choroidal neovascularization (CNV) or the progression of GA in subjects with intermediate to advanced dry AMD.

Read the detailed description

Approximately 30 sites will randomize a total of approximately 150 subjects to 1 of 3 treatment arms in a 1:1:1 ratio (50 subjects per arm). Each subject will receive either QA102 or matching placebo BID for up to 15 months.

03

Conditions studied

  • Dry Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Subject must be able to understand and willing to sign a written form (ICF) prior to the initiation of any study-specific procedures.
  • Subject must be age ≥50 years at the time of informed consent.
  • Subject must be able to take oral medications and willing to record daily adherence to taking their assigned capsules.
  • Subject must have adequate hematologic function, hepatic function, renal function and coagulation profile as defined in the protocol.
  • Subject must be willing and able to comply with study procedures and examinations.

Specific to the Study Eye:

  • Subject must have one of the following:

    • extensive intermediate-size drusen, or at least 1 large drusen, or
    • GA ((not involving the foveal center point) secondary to AMD, with very limited aggregate size of total GA(s), as defined in the protocol.
  • Subject must be able to correctly identify ≥35 ETDRS letters (approximately 20/200 Snellen equivalent).

Specific to Fellow Eye:

- Subject must have a diagnosis of advanced AMD (evidence of GA and/or CNV), to be confirmed by the CRC.

Specific to Both Eyes:

- Subject must have visualizable retina, clear ocular media, and adequate pupillary dilation to ensure high-quality fundus imaging.

Key Exclusion Criteria:

  • Subject received an active drug within 6 weeks (or 5 half-lives of the active, whichever is longer) prior to screening for this QA102 study.
  • Subject has ever received gene therapy (for any condition).
  • Subject is unwilling to stop intake of Age-Related Eye Disease Studies (AREDS) vitamins for the duration of the study.
  • Subject has a systemic disease that might interfere with the study, in the judgment of the Investigator.
  • Subject had major surgery within 30 days prior to Screening.

Specific to Study Eye:

  • Subject has large GA, subfoveal GA, or active or inactive CNV, as confirmed by the CRC.
  • Subject has GA or CNV due to causes other than AMD that that developed between Visit 1 (Screening) and Visit 2 (Randomization).
  • Subject has endophthalmitis.
  • Subject has a hemorrhagic or serous pigment epithelial detachment (PED) within 500 µm of the foveal center point, to be confirmed by the CRC.
  • Subject has had retinal procedures or surgeries, or has a retinal pathology, such as a macular hole.
  • Subject has aphakia or absence of the posterior capsule.
  • Subject has ever received, whether in an interventional trial or by prescription, an FDA- approved treatment for GA. Use of such treatment during the QA102 study period also is prohibited. (Study Eye Only)

Specific to Fellow Eye:

Subject has monocular vision impairment, defined as having no light perception in the fellow eye with adequate vision in the study eye.

Specific to Either Eye:

  • Subject had intraocular surgery with lens replacement within 3 months of Screening.
  • Subject has any ophthalmic condition that could require surgery during the study period.
  • Subject has an ocular condition that might affect adequate imaging of the retina and/or or alter visual acuity.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    QA102 200mg group

    Subjects randomized to this arm will receive one (1) 200 mg capsule of QA102 and 1 placebo capsule BID = daily dose of 400 mg QA102 for up to 15 months

    Drug: QA102/Placebo

  • Experimental
    QA102 400mg group

    Subjects randomized to this arm will receive two (2) 200 mg capsules of QA102 BID = daily dose of 800 mg QA102 for up to 15 months

    Drug: QA102

  • Placebo comparator
    Placebo group

    Subjects randomized to this arm will receive two (2) placebo capsules BID = daily dose of 0 mg QA102 for up to 15 months

    Drug: Placebo

Interventions

  • DrugQA102/Placebo

    Capsules

  • DrugQA102

    Capsules

  • DrugPlacebo

    Capsules

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Soft Drusen Volume (mm3)

    Change from baseline in soft drusen volume (mm3), Efficacy-Evaluable Analysis Set

    Time frame: Month 12

Secondary outcomes

  1. Mean Rate of GA Growth

    Mean Rate of Growth in GA (mm2) (Square Root Transformation) from Baseline

    Time frame: Month 12

07

Results

Posted Oct 1, 2026

Participant flow

Participant flow — Overall Study
MilestoneQA102 200mg GroupQA102 400mg GroupPlacebo Group
Started504951
Completed343739
Not completed161212

Outcome measures

PrimaryChange From Baseline in Soft Drusen Volume (mm3)

Change from baseline in soft drusen volume (mm3), Efficacy-Evaluable Analysis Set

Time frame:
Month 12
Reported as:
Mean · mm3
Change From Baseline in Soft Drusen Volume (mm3)
mm3QA102 200mg GroupQA102 400mg GroupPlacebo Group
Change From Baseline in Soft Drusen Volume (mm3)0.057 ± 0.13320.033 ± 0.12030.081 ± 0.1160
SecondaryMean Rate of GA Growth

Mean Rate of Growth in GA (mm2) (Square Root Transformation) from Baseline

Time frame:
Month 12
Reported as:
Mean · mm2/year
Mean Rate of GA Growth
mm2/yearQA102 200mg GroupQA102 400mg GroupPlacebo Group
Mean Rate of GA Growth0.157 (0.088 to 0.227)0.125 (0.068 to 0.181)0.218 (0.158 to 0.278)

Adverse events

Collected over from enrollment until end of follow-up, up to 15 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
QA102 200mg Group0/50 (0%)12/50 (24%)22/50 (44%)
QA102 400mg Group0/49 (0%)6/49 (12.2%)21/49 (42.9%)
Placebo Group0/51 (0%)4/51 (7.8%)18/51 (35.3%)
Most frequent serious events
Most frequent serious events
EventQA102 200mg GroupQA102 400mg GroupPlacebo Group
Cardiac disordersCardiac disorders4/500/490/51
Infections and infestationsInfections and infestations2/503/491/51
Musculoskeletal and connective tissueMusculoskeletal and connective tissue disorders2/500/491/51
Gastrointestinal disordersGastrointestinal disorders0/501/491/51
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Neoplasms benign, malignant and unspecified (incl cysts and polyps)1/501/491/51
Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders1/501/490/51
Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications1/500/491/51
Renal and urinary disordersRenal and urinary disorders1/500/490/51
Surgical and medical proceduresSurgical and medical procedures1/500/490/51
Vascular disordersVascular disorders1/500/490/51
Most frequent other events
Showing 10 of 14
Most frequent other events
EventQA102 200mg GroupQA102 400mg GroupPlacebo Group
DiarrhoeaGastrointestinal disorders11/508/493/51
COVID-19Infections and infestations5/503/494/51
VomitingGastrointestinal disorders5/500/490/51
NauseaGastrointestinal disorders4/504/490/51
Abdominal pain upperGastrointestinal disorders0/504/490/51
ArthralgiaMusculoskeletal and connective tissue disorders0/504/491/51
Vision blurredEye disorders0/504/491/51
Neovascular age-related macular degenerationEye disorders3/500/494/51
CoughRespiratory, thoracic and mediastinal disorders0/501/494/51
ConstipationGastrointestinal disorders3/501/493/51

Baseline characteristics

Baseline Analysis was presented based on Full Analysis Set (FAS), which included all randomized subjects who received any study medication and who provided a baseline BCVA measurement and at least 1 post-baseline BCVA measurement. One participant randomized but was not included in FAS.

Age, Continuous
Age, Continuous(years)QA102 200mg GroupQA102 400mg GroupPlacebo GroupTotal
Mean75.1 ± 7.5073.8 ± 7.2876.4 ± 7.7975.1 ± 7.55
Sex: Female, Male
Sex: Female, Male(Participants)QA102 200mg GroupQA102 400mg GroupPlacebo GroupTotal
Female33292789
Male17192460
Race (NIH/OMB)
Race (NIH/OMB)(Participants)QA102 200mg GroupQA102 400mg GroupPlacebo GroupTotal
American Indian or Alaska Native0000
Asian0112
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White504549144
More than one race0112
Unknown or Not Reported0101
Region of Enrollment
Region of Enrollment(participants)QA102 200mg GroupQA102 400mg GroupPlacebo GroupTotal
United States504851149
Drusen Volumn in the Study Eye
Drusen Volumn in the Study Eye(mm3)QA102 200mg GroupQA102 400mg GroupPlacebo GroupTotal
Mean1.141 ± 0.22301.128 ± 0.23061.063 ± 0.19071.108 ± 0.2198
GA Area in the Study Eye
GA Area in the Study Eye(mm2)QA102 200mg GroupQA102 400mg GroupPlacebo GroupTotal
Mean0.842 ± 0.67511.270 ± 0.91770.991 ± 0.68481.023 ± 0.7720
08

Study locations

29 sites
  • Associated Retina Consultants
    Phoenix, Arizona 85021, United States
  • Northern California Retina Vitreous Associates Medical Group
    Mountain View, California 94040, United States
  • California Eye Specialists Medical Group
    Pasadena, California 91107, United States
  • California Eye Specialists Medical Group
    Redlands, California 91107, United States
  • Retina Consultants of Southern Colorado, P.C.
    Colorado Springs, Colorado 80909, United States
  • Advanced Research
    Deerfield Beach, Florida 33064, United States
  • National Ophthalmic Research Institute
    Fort Myers, Florida 33912, United States
  • MedEye Associates
    Miami, Florida 33143, United States
  • Retina Specialty Institute
    Pensacola, Florida 32503, United States
  • Eye Associates of Pinellas
    Pinellas Park, Florida 33782, United States
  • Sarasota Retina Institute
    Sarasota, Florida 34239, United States
  • Vitreous and Retina Consultants
    Winter Haven, Florida 33880, United States
  • Marietta Eye Clinic
    Marietta, Georgia 30060, United States
  • University Retina and Macula Associates
    Oak Forest, Illinois 60452, United States
  • Northeast Louisiana dba Haik Humble Eye Center
    West Monroe, Louisiana 71291, United States
  • The Retina Care Center
    Baltimore, Maryland 21209, United States
  • Cumberland Valley Retina Consultants
    Hagerstown, Maryland 21740, United States
  • Mid Atlantic Retina Specialists
    Hagerstown, Maryland 21740, United States
  • Vitreo-Retinal Associates, P.C.
    Worcester, Massachusetts 01605, United States
  • Retina Research Institute
    St Louis, Missouri 63144, United States
  • Velocity Clinical Research
    Cincinnati, Ohio 45202, United States
  • Verum Research, LLC
    Eugene, Oregon 97401, United States
  • Erie Retina Research
    Erie, Pennsylvania 16507, United States
  • Retina Research Institute of Texas
    Abilene, Texas 79606, United States
  • Austin Research Center for Retina
    Austin, Texas 78705, United States
  • AXIS Clinicals LLC / Retina of North Texas
    Dallas, Texas 75243, United States
  • Texas Retina Associates - Plano
    Plano, Texas 75075, United States
  • San Antonio Eye Center
    San Antonio, Texas 78215, United States
  • Rocky Mountain Retina Consultants
    Salt Lake City, Utah 84107, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Nov 2024, 25 months.

Results were first posted in Oct 2026, 1 year 10 months after primary completion.

Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 25 months is above that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2022
First posted
Sep 13, 2022
StartActual
Sep 22, 2022
Primary completionActual
Nov 12, 2024
CompletionActual
Nov 12, 2024
Results first posted
Oct 1, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 1, 2026
Sites
28 sites added
Show 28 added (28 United States)
  • Associated Retina Consultants · Phoenix, United States
  • Northern California Retina Vitreous Associates Medical Group · Mountain View, United States
  • California Eye Specialists Medical Group · Pasadena, United States
  • California Eye Specialists Medical Group · Redlands, United States
  • Retina Consultants of Southern Colorado, P.C. · Colorado Springs, United States
  • Advanced Research · Deerfield Beach, United States
  • National Ophthalmic Research Institute · Fort Myers, United States
  • MedEye Associates · Miami, United States
  • Retina Specialty Institute · Pensacola, United States
  • Eye Associates of Pinellas · Pinellas Park, United States
  • Sarasota Retina Institute · Sarasota, United States
  • Vitreous and Retina Consultants · Winter Haven, United States
  • Marietta Eye Clinic · Marietta, United States
  • University Retina and Macula Associates · Oak Forest, United States
  • Northeast Louisiana dba Haik Humble Eye Center · West Monroe, United States
  • The Retina Care Center · Baltimore, United States
  • Cumberland Valley Retina Consultants · Hagerstown, United States
  • Mid Atlantic Retina Specialists · Hagerstown, United States
  • Vitreo-Retinal Associates, P.C. · Worcester, United States
  • Retina Research Institute · St Louis, United States
  • Velocity Clinical Research · Cincinnati, United States
  • Verum Research, LLC · Eugene, United States
  • Erie Retina Research · Erie, United States
  • Retina Research Institute of Texas · Abilene, United States
  • Austin Research Center for Retina · Austin, United States
  • AXIS Clinicals LLC / Retina of North Texas · Dallas, United States
  • San Antonio Eye Center · San Antonio, United States
  • Rocky Mountain Retina Consultants · Salt Lake City, United States
Oct 1, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange from baselineFrom Baseline in soft drusen volumeSoft Drusen Volume (mm3)Time frame: Month 12
Oct 1, 2026
Secondary outcomes
1 edited, 13 removed
What changed in the outcomes
  • EditedMean rateRate of GA growthGrowthTime frame: Month 1,2,3,6,9,12,15 → Month 12
  • RemovedChange from Baseline in BCVATime frame: Month 12
  • RemovedChange from Baseline in LLVATime frame: Month 12
  • RemovedChange from baseline in soft drusen volume (mm3)Time frame: Month 1,2,3,6,9,12,15
  • RemovedChange from Baseline in BCVATime frame: Month 1,2,3,6,9,12,15
  • RemovedChange from Baseline in LLVATime frame: Month 1,2,3,6,9,12,15
  • RemovedChange from baseline in GATime frame: Month 1,2,3,6,9,12,15
  • RemovedChange from baseline in GATime frame: Month 1,2,3,6,9,12,15
  • RemovedArea under the curve for BCVA lettersTime frame: Month 1,2,3,6,9,12,15
  • RemovedProportion of subjects with disease progressionTime frame: Month 15
  • RemovedProportion of subjects with progression of GATime frame: Month 1,2,3,6,9,12,15
  • RemovedRescue injectionsTime frame: Month 1,2,3,6,9,12,15
  • RemovediRORATime frame: Month 1,2,3,6,9,12,15
  • RemovedFellow eye CNVTime frame: Month 1,2,3,6,9,12,15
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Results posted
    28 sites added
    Show 28 added (28 United States)
    • Associated Retina Consultants · Phoenix, United States
    • Northern California Retina Vitreous Associates Medical Group · Mountain View, United States
    • California Eye Specialists Medical Group · Pasadena, United States
    • California Eye Specialists Medical Group · Redlands, United States
    • Retina Consultants of Southern Colorado, P.C. · Colorado Springs, United States
    • Advanced Research · Deerfield Beach, United States
    • National Ophthalmic Research Institute · Fort Myers, United States
    • MedEye Associates · Miami, United States
    • Retina Specialty Institute · Pensacola, United States
    • Eye Associates of Pinellas · Pinellas Park, United States
    • Sarasota Retina Institute · Sarasota, United States
    • Vitreous and Retina Consultants · Winter Haven, United States
    • Marietta Eye Clinic · Marietta, United States
    • University Retina and Macula Associates · Oak Forest, United States
    • Northeast Louisiana dba Haik Humble Eye Center · West Monroe, United States
    • The Retina Care Center · Baltimore, United States
    • Cumberland Valley Retina Consultants · Hagerstown, United States
    • Mid Atlantic Retina Specialists · Hagerstown, United States
    • Vitreo-Retinal Associates, P.C. · Worcester, United States
    • Retina Research Institute · St Louis, United States
    • Velocity Clinical Research · Cincinnati, United States
    • Verum Research, LLC · Eugene, United States
    • Erie Retina Research · Erie, United States
    • Retina Research Institute of Texas · Abilene, United States
    • Austin Research Center for Retina · Austin, United States
    • AXIS Clinicals LLC / Retina of North Texas · Dallas, United States
    • San Antonio Eye Center · San Antonio, United States
    • Rocky Mountain Retina Consultants · Salt Lake City, United States
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange from baselineFrom Baseline in soft drusen volumeSoft Drusen Volume (mm3)Time frame: Month 12
    Secondary outcomes 1 edited, 13 removed
    What changed in the outcomes
    • EditedMean rateRate of GA growthGrowthTime frame: Month 1,2,3,6,9,12,15 → Month 12
    • RemovedChange from Baseline in BCVATime frame: Month 12
    • RemovedChange from Baseline in LLVATime frame: Month 12
    • RemovedChange from baseline in soft drusen volume (mm3)Time frame: Month 1,2,3,6,9,12,15
    • RemovedChange from Baseline in BCVATime frame: Month 1,2,3,6,9,12,15
    • RemovedChange from Baseline in LLVATime frame: Month 1,2,3,6,9,12,15
    • RemovedChange from baseline in GATime frame: Month 1,2,3,6,9,12,15
    • RemovedChange from baseline in GATime frame: Month 1,2,3,6,9,12,15
    • RemovedArea under the curve for BCVA lettersTime frame: Month 1,2,3,6,9,12,15
    • RemovedProportion of subjects with disease progressionTime frame: Month 15
    • RemovedProportion of subjects with progression of GATime frame: Month 1,2,3,6,9,12,15
    • RemovedRescue injectionsTime frame: Month 1,2,3,6,9,12,15
    • RemovediRORATime frame: Month 1,2,3,6,9,12,15
    • RemovedFellow eye CNVTime frame: Month 1,2,3,6,9,12,15
    + 4 other changes: verification date, criteria formatting, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05536752
Lead sponsor
Smilebiotek Zhuhai Limited
Responsible party
Sponsor
First posted
Sep 13, 2022
Start date
Sep 22, 2022
Primary completion
Nov 12, 2024
Completion
Nov 12, 2024
Results posted
Oct 1, 2026
Last update
Oct 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion